Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 156

TransUnion picks up Signal

Yahoo Japan has exited the customer intelligence software provider in an acquisition of undisclosed size by TransUnion following more than $78m in funding.

Aug 19, 2020

DesignMedix gives up after failed trial

Portland State University spinout DesignMedix has shut down after its phase 1 trial for an antimalaria treatment caused side effects.

Aug 19, 2020

JW Therapeutics to jump to public markets

The immuno-oncology company – co-founded by Juno Therapeutics, a spinout of several institutions – is reportedly seeking $250m to $300m in a Hong Kong offering.

Aug 18, 2020

American Express to eat up Kabbage

American Express will acquire the SoftBank, UPS, Santander and Recruit-backed business lender's assets excluding its loan portfolio, for a reported price $350m lower than the valuation for its last round.

Aug 18, 2020

JW Therapeutics to jump to public markets

WuXi AppTec and Juno Therapeutics' immuno-oncology joint venture is reportedly seeking $250m to $300m in a Hong Kong offering.

Aug 18, 2020

Arctech attacks $207m initial public offering

The solar tracking technology provider is aiming for $207m in an IPO on Shanghai's Star Market having raised money in a Risen Solar-backed round last year.

Aug 18, 2020

WMG tunes into IMGN Media acquisition

Dick Clark Productions, Keshet and UTA have exited the online meme and video producer in a Warner Media Group purchase reportedly sized at about $85m.

Aug 18, 2020

Nano-X plans $106m IPO target

Existing investors including Foxconn, SK Telecom and iA Financial could buy up to $80m of shares in the medical imaging system developer's initial public offering.

Aug 17, 2020

CureVac comes to public markets in $213m IPO

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.

Aug 14, 2020

CureVac comes to public markets in $213m IPO

GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

Aug 14, 2020
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here